Novo Nordisk A/S (NVO) News

Novo Nordisk is aggressively integrating artificial intelligence into its core operations to combat fierce competition and declining market share in the obesity drug sector. The strategic partnership with OpenAI represents a critical pivot as the Danish pharmaceutical giant attempts to revitalize its pipeline and defend its franchise against Eli Lilly's expanding dominance.

Novo Nordisk concluded 2025 with robust double-digit sales growth driven by its obesity franchise, but shocked investors with guidance projecting a contraction for 2026. While the rapid uptake of its newly launched oral Wegovy demonstrates undeniable consumer demand, mounting competitive price pressures and generics present significant hurdles for the pharmaceutical giant's near-term profitability.